ENB Therapeutics’ Orphan Drug, Endothelin Receptor Type B Target for Resistant Cancers February 15, 2023
2 Women-Founded Companies are Optimizing Targeted Lipid Nanoparticle mRNA Therapies for a Rare Respiratory DiseaseFebruary 3, 2023
Feature Stories ENB Therapeutics’ Orphan Drug, Endothelin Receptor Type B Target for Resistant Cancers By Radhika ShahFebruary 15, 2023Last week, President and Co-Founder Sumayah Jamhal presented her company, ENB Therapeutics, at the 2023 Immuno-Oncology 360 Degree Conference in… Read More
